Epogen
(Amgen); Procrit (Ortho Biotech).
Epoetin alfa, rEPO (Epogen, Procrit), isthe recombinant human erythropoietin produced in Chinesehamster ovary cells into which the human erythropoietin genehas been inserted. These mammalian cells glycosylate theprotein in a manner similar to that observed in human cells.
Epoetin alfa is indicated in anemic patients with chronicrenal failure, including both those who require regular dialysisand those who do not. Epoetin alfa is also indicated inanemia associated with AIDS, treatment of AIDS with zidovudine,frequent blood donations, and neoplastic diseases.It is indicated to prevent anemia in patients who donateblood prior to surgery for future autologoustransfusions and to reduce the need for repeated maintenancetransfusions. The hormone is available as an isotonicbuffered solution, which is administered by the intravenousroute. The solution should not be frozen or shakenand is stored at 36°F to 46°F.
Epoetin Alfa, recombinant Erythropoietin alfa, Epogen,Procrit, is a glycoprotein that stimulates red blood cellproduction. It is produced in the kidney, and it activates theproliferation and differentiation of specially committed erythroidprogenitors in the bone marrow.
Epoetin is indicated to treat anemia of chronic renal failurepatients, anemia in zidovudine-treated HIV-infectedpatients, and in cancer patients taking chemotherapy. Theresults in these cases have been dramatic; most patients respondwith a clinically significant increase in hematocrit.
Veterinary Drugs and Treatments
EPO has been used to treat dogs and cats for anemia associated with
chronic renal
failure. Some clinicians state that because of the expense
and potential risks associated with its use, PCV’s should be in
the “teens” before considering beginning EPO therapy. Development
of antibodies to EPO has severely limited its clinical usefulness in
veterinary medicine for chronic use. EPO may be demonstrated in
the future to have significant benefits in reducing the number or
volume of transfusions, or as a neuroprotective agent.
Potentially hazardous interactions with other drugs
Hyperkalaemia with ACE inhibitors and
angiotensin-II antagonists
The metabolic fate of both endogenous and recombinant
erythropoietin is poorly understood. Current evidence
from studies in animals suggests that hepatic metabolism
contributes only minimally to elimination of the intact
hormone, but desialylated epoetin (i.e. terminal sialic
acid groups removed) appears to undergo substantial
hepatic clearance via metabolic pathways and/or binding.
Desialylation and/or removal of the oligosaccharide side
chains of erythropoietin appear to occur principally in
the liver; bone marrow also may have a role in catabolism
of the hormone. Elimination of desialylated drug by the
kidneys, bone marrow, and spleen also may occur; results
of animal studies suggest that proximal renal tubular
secretion may be involved in renal elimination.
